Bayesian Capital Management, LP Fibrogen Inc Transaction History

Bayesian Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$7.94 - $12.96 $141,983 - $231,750	17,882 New	17,882 $189,000
Q2 2021 Aug 13, 2021	SELL	$18.57 - $35.68 $111,420 - $214,080	-6,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$31.0 - $55.72 $186,000 - $334,320	6,000 New	6,000 $208,000
Q4 2017 Feb 12, 2018	SELL	$41.95 - $60.1 $486,494 - $696,979	-11,597 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $387,339 - $625,078	11,597	11,597 $624,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.